Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

By Roehrborn C.G.   Boyle P.   Nickel J.C.   Hoefner K.   Andriole G.   the ARIA3001 ARIA3002 and ARIA3003 Study Investigators  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 434-441

Elsevier

Access to resources Recommend Favorite

Dual 5 -reductase inhibitor, dutasteride, inhibits androgen action, cell growth/viability in prostate cancer cell lines

By Lazier C.   Thomas L.   Douglas R.   Schmidt L.   Tindall D.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 37-37

Elsevier

Access to resources Recommend Favorite

Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

By Andriole G.L.   Kirby R.  

European Urology, Vol. 44, Iss. 1, 2003-07 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression

By Nam R.K.   Toi A.   Vesprini D.   Ho M.   Chu W.   Harvie S.   Sweet J.   Trachtenberg J.   Jewett M.A.S.   Narod S.A.  

Urology, Vol. 57, Iss. 1, 2001-01 ,pp. : 199-204

Elsevier

Access to resources Recommend Favorite

Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study

By Klarskov Louise L.  

Scandinavian Journal of Urology and Nephrology, Vol. 46, Iss. 1, 2012-02 ,pp. : 37-43

Informa Healthcare

Access to resources Recommend Favorite